tislelizumab
Tevimbra Approved for Some Patients With Unresectable or Metastatic ESCC
The FDA has approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment ...
MARCH 4, 2025
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 21, 2023
Load more